Asia-Pacific Insulin Delivery Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 18.88 Billion |
| Market Size (2029) | USD 21.55 Billion |
| CAGR (2024 - 2029) | 2.68 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Asia-Pacific Insulin Delivery Devices Market Analysis
The Asia-Pacific Insulin Delivery Devices Market size is estimated at USD 18.88 billion in 2024, and is expected to reach USD 21.55 billion by 2029, growing at a CAGR of greater than 2.68% during the forecast period (2024-2029).
The occurrence of newly detected cases of Type 1 and Type 2 diabetes is observed to be on the rise, primarily attributed to factors such as obesity, unhealthy eating habits, and lack of physical activity.
The escalating number of individuals diagnosed with diabetes and the subsequent increase in healthcare expenses in developed nations serve as clear indicators of the growing utilization of diabetic care products. Furthermore, the market growth is propelled by the surging adoption of insulin-delivery devices and the expanding prevalence of diabetes. Prominent manufacturers are directing their efforts towards technological advancements and the creation of cutting-edge products in order to secure a significant market share.
According to the International Diabetes Federation (IDF), the IDF South-East Asia (SEA) Region is home to 90 million adults (aged 20-79) living with diabetes in 2021. This number is projected to rise to 152 million by 2045. In the IDF Western Pacific Region, there are currently 206 million adults (aged 20-79) living with diabetes in 2021, and this is expected to increase to 260 million by 2045.
The primary cause of diabetes is the imbalance in blood glucose levels, which deviate from the standard levels. Physicians can diagnose the disease through general lab diagnostic tests. However, individuals with greater fluctuations in glucose levels should monitor their levels daily. Those who require insulin must frequently check their blood glucose levels, adjust insulin doses, or consider changing their medication if necessary.
The Asia-Pacific region has witnessed an astounding increase in the prevalence of diabetes in patients, in recent years. The increasing demand for insulin has led to great R&D in manufacturing different, painless types of insulin deliverable devices, like CGM-integrated insulin pumps. Traditionally, insulin syringes were the only form of insulin delivery system, which were considered to be painful and not user-friendly. Furthermore, the dosage may not be accurate. Thus, companies, like Novo Nordisk and Sanofi, among others, have bought their insulin pens in the market. These pens have a specific set of dosages and are considered to be not only less painful to use, but also reduce wastage of insulin. The high cost of insulin pens is the only prominent restraining factor for the growth of the pens market.
Asia-Pacific Insulin Delivery Devices Market Trends
Japan Holds the Major Market Share in the Asia-Pacific Insulin Delivery Devices Market in the current year
Japan accounted for 41% of the Asia-Pacific insulin delivery devices market share. In developing countries, such as Japan, China, and India, the rate of diabetes among the population is growing, mainly due to the unhealthy lifestyle of the population. The increasing geriatric population in Japan is driving the insulin delivery devices market. The changing lifestyle trends and high disposable income among the population are prominent driving factors for the sales of insulin delivery devices.
Insulin was initially considered to be the treatment method only for type-1 patients. However, over the years, insulin is also used by many type-2 patients as a line of treatment. According to IDF 2022 figures, around 11 million persons include diabetes in Japan. Diabetes became a global epidemic. Type 2 diabetes is related to adopting a sedentary lifestyle, which develops innate resistance to insulin, in contrast to Type 1 diabetes, which is brought on by an immune system failure. As a result, Type 1 diabetes is known as insulin-required diabetes, and Type 2 diabetes is known as insulin-dependent diabetes. One of the greatest senior populations in the world is found in Japan, where type 2 diabetes is more likely to develop. As Japan's population continues to age, diabetes is becoming more common. Blood glucose levels are increasingly monitored and managed to prevent adverse effects like cardiovascular disorders.
The Ministry of Health, Labour, and Welfare (MHLW) includes designated diabetes as a top healthcare priority. A large economic cost is associated with the high incidence of type 2 diabetes. Patients with co-morbid conditions, including hypertension and hyperlipidemia, and those with complications include higher diabetes expenditures. Costs grow when there are more issues. People with diabetes can freely see doctors in Japan because of well-organized medical insurance systems that pay for all costs associated with treating diabetes mellitus.
Additionally, self-injection of insulin for treatment is made lawful and is now covered by insurance. The Japan Association for Diabetes Education and Care runs several disease management programs for the Japanese healthcare system. Regarding diabetes care, Japan is one of the Asia-Pacific region's leaders.
Disposable pens includes highest market share in the Asia-Pacific Region.
The Asia-Pacific market for Insulin Disposable pens is valued at more than USD 7.5 billion in the current year, with 39% of the market share. It contains a prefilled insulin cartridge. Once used, the entire pen unit is thrown away. Insulin in pens and cartridges is generally more expensive than bottled insulin and syringes. Insulin cartridges in reusable pens are known to be a needed extension to insulin pens. A small quantity of insulin is wasted when pens are used, making the process less economical. A large set of diabetic type-1 patients is children. There is a need for an alternative to the existing needle-based delivery system, which is painful. Thus, an insulin jet injector, a painless insulin delivery system, was introduced. Most types of insulins are manufactured in the form of cartridges, thus, making them easily accessible. These devices include all the functional benefits of reusable pens and are cost-effective, as these cartridges are less expensive when compared to disposable insulin pens in the long run.
In recent years, diabetes prevalence alarmingly increased in the Asia-Pacific area. Diabetes is becoming more prevalent in developing nations like China and India. Patients with diabetes must make several adjustments during the day to keep their blood glucose levels within acceptable ranges. Examples include taking oral anti-diabetic medicine or consuming more carbs while monitoring their blood glucose levels. Leading manufacturers are concentrating on technical advancements and creating cutting-edge items to capture a sizeable portion of the market.
It is therefore anticipated to drive the category expansion during the projected period due to the factors above.
Asia-Pacific Insulin Delivery Devices Industry Overview
The market is consolidated, with few players holding a significant market share in the current year. However, the insulin syringe market is highly fragmented, and many market players are based locally. Companies to expand their market presence are investing in R&D and collaborating with other major players to develop innovative solutions. Abbott and Novo Nordisk partnered to provide an integrated digital solution to people with diabetes using insulin. The collaboration may enable insulin data to be shared between Novo Nordisk's connected insulin pens and digital health tools compatible with the FreeStyle Libre portfolio of products.
Asia-Pacific Insulin Delivery Devices Market Leaders
-
Novo Nordisk
-
Medtronic
-
Sanofi
-
Eli Lilly and Company
-
Ypsomed Holding
*Disclaimer: Major Players sorted in no particular order
Asia-Pacific Insulin Delivery Devices Market News
- NOV 2022: The Albanese Government is changing the lives of the 130,000 Australians with type 1 diabetes by subsidizing access to the next generation of Omnipod insulin pumps.
- MAR 2022: Medtronic India announced the MiniMed 780G system launch in India. The MiniMed 780G system is a next-generation closed-loop insulin pump system for treating type 1 diabetes in people aged 7-80 years.
Asia-Pacific Insulin Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Defination
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
-
5.1 Device
- 5.1.1 Insulin Pump
- 5.1.1.1 By Technology
- 5.1.1.1.1 Tethered Insulin Pump
- 5.1.1.1.2 Tubeless Insulin Pump
- 5.1.1.2 By Component
- 5.1.1.2.1 Insulin Pump Device
- 5.1.1.2.2 Insulin Pump Reservoir
- 5.1.1.2.3 Infusion Set
- 5.1.2 Insulin Pens
- 5.1.2.1 Cartridges in Reusable Insulin Pens
- 5.1.2.2 Disposable Insulin Pens
- 5.1.3 Insulin Syringes
- 5.1.4 Insulin Jet Injectors
-
5.2 Geography
- 5.2.1 Australia
- 5.2.2 India
- 5.2.3 Indonesia
- 5.2.4 Thailand
- 5.2.5 Philippines
- 5.2.6 Vietnam
- 5.2.7 China
- 5.2.8 South Korea
- 5.2.9 Japan
- 5.2.10 Malaysia
- 5.2.11 Rest of Asia-Pacific
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Becton and Dickenson
- 7.1.2 Medtronic
- 7.1.3 Insulet
- 7.1.4 Tandem
- 7.1.5 Ypsomed Holding
- 7.1.6 Novo Nordisk
- 7.1.7 Sanofi
- 7.1.8 Eli Lilly and Company
- *List Not Exhaustive
-
7.2 Company Share Analysis
- 7.2.1 Medtronic
- 7.2.2 Novo Nordisk
- 7.2.3 Eli Lilly and Company
- 7.2.4 Others
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAsia-Pacific Insulin Delivery Devices Industry Segmentation
Insulin injections under the skin are the most popular method of administering insulin. Insulin can be administered subcutaneously using various devices, including insulin pens, pumps, vials, and syringes. The study provides a detailed analysis of the insulin delivery devices market in the Asia-Pacific region and includes market share, size, forecast, and industry overview. Asia-Pacific Insulin Delivery Devices Market is segmented by devices (Insulin Pens (cartridges in reusable insulin pens, and disposable insulin pens), insulin syringes, insulin jet injectors, insulin pumps (Technology ( Tethered Insulin Pump, Tubeless Insulin Pump) and by Components (insulin pump device, insulin pump reservoir, and infusion set). The report offers the value (in USD) and volume (in units) for the above segments. We will provide a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.
| Device | Insulin Pump | By Technology | Tethered Insulin Pump |
| Tubeless Insulin Pump | |||
| Device | Insulin Pump | By Component | Insulin Pump Device |
| Insulin Pump Reservoir | |||
| Infusion Set | |||
| Device | Insulin Pens | Cartridges in Reusable Insulin Pens | |
| Disposable Insulin Pens | |||
| Device | Insulin Syringes | ||
| Insulin Jet Injectors | |||
| Geography | Australia | ||
| India | |||
| Indonesia | |||
| Thailand | |||
| Philippines | |||
| Vietnam | |||
| China | |||
| South Korea | |||
| Japan | |||
| Malaysia | |||
| Rest of Asia-Pacific |
Asia-Pacific Insulin Delivery Devices Market Research FAQs
How big is the Asia-Pacific Insulin Delivery Devices Market?
The Asia-Pacific Insulin Delivery Devices Market size is expected to reach USD 18.88 billion in 2024 and grow at a CAGR of greater than 2.68% to reach USD 21.55 billion by 2029.
What is the current Asia-Pacific Insulin Delivery Devices Market size?
In 2024, the Asia-Pacific Insulin Delivery Devices Market size is expected to reach USD 18.88 billion.
Who are the key players in Asia-Pacific Insulin Delivery Devices Market?
Novo Nordisk, Medtronic, Sanofi, Eli Lilly and Company and Ypsomed Holding are the major companies operating in the Asia-Pacific Insulin Delivery Devices Market.
What years does this Asia-Pacific Insulin Delivery Devices Market cover, and what was the market size in 2023?
In 2023, the Asia-Pacific Insulin Delivery Devices Market size was estimated at USD 18.39 billion. The report covers the Asia-Pacific Insulin Delivery Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Insulin Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Diabetes Pen in Asia Pacific Industry Report
Statistics for the 2024 Diabetes Pen in Asia Pacific market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Diabetes Pen in Asia Pacific analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
